The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Keep the faith. Thats all weve got.
no GM notice. Very strange.
Agree, I am down some £25k on this, not small change unfortunately. I still believe the product is needed and hope someone will pick it up and get it to market
Certainly needs some careful investigation depending on where the business ends up. As I said watching the share trading on the drop from 40p to below 5p I felt for those PIs who had lost a lot, perhaps most of their investments. I think some kind of Q&A session at the very least. From what I've been able to understand the FDA concern on liver toxicity should have been identified in the risk assessment given the drugs history with that regard and therefore should not have been overlooked since it would have been obvious that the FDA would want some assurance... Someone with more experience would be able to comment better...
Where does incompetence end (lack of due diligence/data review, failing to appreciate the impact of the profound hepatotoxicity of the oral formulation (as admitted by Arpida in 2009 AR) on IV development) and negligence (wilfully ignoring/disregarding/hiding negative/problematic data) start? Shareholders must have some comeback surely?
If the board had appreciation for the losses suffered by long term shareholders would they not have taken some sacrifice of their substantial salaries in the light of the parlous financial position of the company? The shareholders have suffered yet another blow through the substantial dilution suffered from the recent share placing which in part provides cash for paying those salaries.
Incompetence is one things , but in my view this indicates gross insensitivity.
even the book is pants 1.5m 44 v 67.
Dunno why the auto bods are still interested really.
I've held these for a long time. The product is needed, we are running out of effective antibiotics. It's a major issue. In my opinion it will get bought because of that need and the fact that there are few new antibiotics in development. Whether or not shareholders see the value or not is another matter. It was sad to see all the sells coming thorough on the day of the FDA announcement and to appreciate the losses those trades represented. I am sure in some instances it was peoples main 'punt' or savings. I hope the Board appreciate the real losses people have had here and do their best to get some value back to the ordinary shareholder.